Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
InMode Ltd(INMD)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for INMD
09/25/2026: INMD (1-star) is currently NOT-A-BUY. Pass it for now.
InMode Ltd is a manufacturer of minimally invasive and non-invasive aesthetic medical platforms, known for its high-margin revenue model driven by RF technology such as Morpheus8. The company has historically maintained a strong position with a debt-free balance sheet and robust cash generation, making it a potentially attractive option for value-oriented investors seeking exposure to medical aesthetics. While the company has seen explosive growth, it currently faces challenges from slowing demand and intense competition, which have introduced volatility. Investors should monitor the company's ability to innovate, manage market saturation, and navigate macroeconomic cycles. Overall, InMode is a focused aesthetic device player suited for those comfortable with sector-specific volatility.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company remains a growth-oriented business but is currently navigating a period of decelerating revenue growth. |
| Momentum investor | Weak fit | The stock lacks strong upward price momentum in the current technical environment. |
| Value investor | Strong fit while signal remains positive | The company's significant cash position and historically low price-to-earnings ratios may appeal to value-oriented investors. |
| Dividend investor | Weak fit | InMode does not pay a dividend and focuses capital on growth and buybacks. |
| Low-risk investor | Weak fit | The stock experiences high beta and price volatility common in small-to-mid-cap aesthetic medical device makers. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to significant daily fluctuations driven by sentiment in the aesthetics sector. |
| Valuation risk | Medium | While trading at lower multiples than in the past, potential for downward valuation re-rating exists if growth continues to slow. |
| Competition risk (aesthetic device makers) | High | New entrants and established players continuously challenge InMode's Morpheus8 market share. |
| Business quality | Strong | The company has demonstrated long-term, high-margin, and capital-efficient operations. |
| Dividend income | Low / none | Investors should not expect income from this stock. |
| Execution risk | Medium | The management team must successfully navigate market saturation to maintain current performance levels. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -47.92% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 816.55M USD | Price to earnings Ratio 11.73 | 1Y Target Price 16.17 |
Price to earnings Ratio 11.73 | 1Y Target Price 16.17 | ||
Volume (30-day avg) 487.1K shares | Beta 1.86 | 52 Weeks Range 12.72 - 16.74 | Updated Date 09/24/2026 |
52 Weeks Range 12.72 - 16.74 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.21 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Equipment Sales | Sale of BodyTite, FaceTite, and Morpheus8 platforms to plastic surgeons and dermatologists. | This is the primary driver of revenue, representing initial capital investment by practitioners. |
| Consumables | Recurring sales of single-use tips and applicators used for each patient treatment. | This provides the high-margin, recurring revenue tailwind that supports long-term profitability. |
| Geography | Significant operations and sales presence in the US, Canada, and various international markets. | Revenue is heavily geographically diversified, though US sales remain the most critical component. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 11.73 | Forward PE 9.99 | Enterprise Value 319.89M | Price to Sales(TTM) 2.18 |
Enterprise Value 319.89M | Price to Sales(TTM) 2.18 | ||
Enterprise Value to Revenue 0.85 | Enterprise Value to EBITDA 4.58 | Shares Outstanding 57.54M | Shares Floating 49.12M |
Shares Outstanding 57.54M | Shares Floating 49.12M | ||
Percent Insiders 13.16 | Percent Institutions 55.96 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About InMode Ltd
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2019-08-08 | Co-Founder, CEO & Director Mr. Moshe Mizrahy | ||
Sector Healthcare | Industry Medical Devices | Full time employees 660 | Website https://www.inmodemd.com |
Full time employees 660 | Website https://www.inmodemd.com | ||
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.